pentobarbital will lessen the extent or result of cannabidiol by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Intently. Contemplate an increase in cannabidiol dosage (dependant on medical response and tolerability) when coadministered with a powerful CYP3A4 inducer.
pentobarbital will lessen the extent or impact of vinblastine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Not known.
pentobarbital will decrease the extent or effect of nimodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unfamiliar.
Contraindicated (1)pentobarbital decreases levels of panobinostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inducers can cut down panobinostat concentrations by ~70% and bring on treatment failure.
pentobarbital will decrease the extent or result of doxorubicin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
pentobarbital will lessen the level or result of glecaprevir/pibrentasvir by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will reduce the level or effect of amlodipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital raises toxicity of ifosfamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check. CYP3A4 inducers may perhaps improve the metabolism of ifosfamide to its active alkylating metabolites.
This drug might interfere Using the absorption of orally administered griseofulvin, reducing its blood degrees; consequences of blood amount reduction unknown; preferable to prevent concomitant administration of such medication
Monitor Carefully (two)pentobarbital will lessen the extent or effect of suvorexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check. Potent CYP3A4 inducers may reduce suvorexant efficacy; if enhanced more info suvorexant dose demanded, never exceed twenty mg/day
pentobarbital will decrease the level or influence of lorlatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will lower the extent or effect of naloxegol by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Utilization of naloxegol with strong CYP3A4 inducers is not recommended
pentobarbital will minimize the level or effect of zaleplon by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unidentified.
pentobarbital will reduce the level or outcome of prednisone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch.